Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and …
J Xia, J Li, L Tian, X Ren, C Liu… - Journal of Medicinal …, 2022 - ACS Publications
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that can change the
expression of downstream target genes by catalyzing the trimethylation of lysine 27 of …
expression of downstream target genes by catalyzing the trimethylation of lysine 27 of …
Therapeutic regulation of epigenetics in cancer treatment through drug delivery systems
B Su, S Li, S Geng, D Brambilla, R Sun, T Sun, C Jiang - Nano Today, 2024 - Elsevier
Not only genetic but also epigenetic factors are closely associated with cancer, especially
with its malignant evolution. Cancer therapies based on epigenetic modulation have …
with its malignant evolution. Cancer therapies based on epigenetic modulation have …
Nano-drug delivery system for the treatment of acute myelogenous leukemia.
S Zhang, J Sun - Zhejiang da xue xue bao. Yi xue ban= Journal of …, 2022 - europepmc.org
药物治疗是急性髓细胞性白血病 (AML) 的核心治疗策略, 但目前的治疗药物普遍存在生物利用
度低, 不良反应大, 静脉给药不便等缺陷. 纳米药物递送系统通过针对性优化药物的递送方式可以 …
度低, 不良反应大, 静脉给药不便等缺陷. 纳米药物递送系统通过针对性优化药物的递送方式可以 …
A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy
Acute myeloid leukemia (AML), which is common in the elderly population, accounts for poor
long-term survival with a high possibility of relapse. The associated lack of currently …
long-term survival with a high possibility of relapse. The associated lack of currently …
[HTML][HTML] Systematic review of epigenetic targets in acute myeloid leukemia
Acute myeloid leukemia (AML), although genetically and morphologically distinct from other
B and T cell ALL subtypes, has one of the most rapidly progressing course and worse …
B and T cell ALL subtypes, has one of the most rapidly progressing course and worse …
Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma
Glioblastoma (GBM) is a complex brain cancer with frequent relapses and high mortality and
still awaits effective treatment. Mitochondria dysfunction is a pathogenic condition in GBM …
still awaits effective treatment. Mitochondria dysfunction is a pathogenic condition in GBM …
Targeting the epigenome with advanced delivery strategies for epigenetic modulators
S Guha, Y Jagadeesan, MM Pandey… - Bioengineering & …, 2024 - Wiley Online Library
Epigenetics mechanisms play a significant role in human diseases by altering DNA
methylation status, chromatin structure, and/or modifying histone proteins. By modulating the …
methylation status, chromatin structure, and/or modifying histone proteins. By modulating the …
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease
MN Sardoiwala, SJ Mohanbhai, S Karmakar… - Biomaterials …, 2022 - Elsevier
Parkinson's disease (PD) is the second most neurodegenerative disease caused due to
synucleinopathy leads to the death of dopaminergic and serotonergic neurons. The …
synucleinopathy leads to the death of dopaminergic and serotonergic neurons. The …
[HTML][HTML] EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer
Y Chen, H Zhu, Y Luo, S Tong, Y Liu - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Drug resistance presents a formidable challenge in the realm of breast cancer therapy.
Accumulating evidence suggests that enhancer of zeste homolog 2 (EZH2), a component of …
Accumulating evidence suggests that enhancer of zeste homolog 2 (EZH2), a component of …
Role of EZH2 in bone marrow mesenchymal stem cells and immune–cancer interactions
Z Liu, Y Jia, Y Guo, H Wang, R Fu - Critical Reviews in Oncology …, 2022 - Elsevier
In recent years, methylation modification has been determined to be vital for the biological
regulation of normal cells, tumor cells, and tumor microenvironment immune cells. Enhancer …
regulation of normal cells, tumor cells, and tumor microenvironment immune cells. Enhancer …